JOURNAL OF CHILEAN CHEMICAL SOCIETY

Vol 70 No 3 (2025): Journal of The Chilean Chemical Society
Original Research Papers

INTEGRATED MOLECULAR DOCKING AND ADMET ANALYSIS OF Hyoscyamus niger METABOLITES TARGETING Α-GLUCOSIDASE AND Α-AMYLASE FOR ANTIDIABETIC THERAPY

PDF
  • Cristian Paz,
  • Muhammad Javid Iqbal ,
  • Viviana Burgos,
  • Cecilia Villegas,
  • Sana Iqbal
Cristian Paz
UFRO
Published November 10, 2025
Keywords
  • Hyoscyamus niger,
  • α-glucosidase,
  • α-amylase,
  • cleomiscosin B,
  • molecular docking,
  • antidiabetic agents
    • ...More
    Less
How to Cite
Paz, C., Iqbal , M. J., Burgos, V., Villegas, C., & Iqbal, S. (2025). INTEGRATED MOLECULAR DOCKING AND ADMET ANALYSIS OF Hyoscyamus niger METABOLITES TARGETING Α-GLUCOSIDASE AND Α-AMYLASE FOR ANTIDIABETIC THERAPY. Journal of the Chilean Chemical Society, 70(3), 6399-6406. Retrieved from https://www.jcchems.com/index.php/JCCHEMS/article/view/2901

Copyright (c) 2025 SChQ

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Abstract

The global diabetes epidemic requires safer therapeutic alternatives to conventional α-glucosidase and α-amylase inhibitors, which cause significant gastrointestinal side effects. Natural products provide structurally diverse scaffolds for antidiabetic drug discovery. This study evaluated the dual enzyme inhibitory potential of Hyoscyamus niger L. (black henbane) through integrated experimental and computational approaches. Methanolic extracts of H. niger seeds were assessed for α-glucosidase and α-amylase inhibitory activities using enzymatic assays. H. niger extract exhibited superior inhibitory activity compared to acarbose, with IC₅₀ values of 35.85 ± 5 μg/mL (α-glucosidase) and 44.56 ± 5 μg/mL (α-amylase) versus acarbose's IC₅₀ values of 141.0 ± 5 μg/mL and 131.0 ± 10 μg/mL, respectively. 100 phytochemicals were subjected to molecular docking against target enzymes (PDB IDs: 3L4Y and 3BAJ). Lead compounds were evaluated for drug-likeness using Lipinski's Rule of Five and comprehensive ADMET profiling. Molecular docking identified one coumarinolignan called cleomiscosin B as the most promising lead compound, demonstrating excellent binding affinities (-8.1 kcal/mol for both enzymes), complete Lipinski compliance, and favorable safety profiles with no AMES toxicity. In spite to pongamoside D was also founded as the top dual-target inhibitor with binding affinities of -9.3 kcal/mol (α-amylase) and -8.3 kcal/mol (α-glucosidase). However, ADMET analysis suggested that pongamoside D violated Lipinski's rule and showed positive AMES toxicity with possible carcinogenicity risk. This study establishes H. niger as a valuable source of novel dual-target antidiabetic compounds, with cleomiscosin B representing a promising alternative to synthetic inhibitors.

2901.jpg

PDF

References

  1. D. Dasgupta and A. Patel, “Enhancing diabetes therapy with pH-sensitive co-delivery of metformin hydrochloride and glipizide using MCM-48-based dual drug delivery system,” RSC Adv, vol. 15, no. 9, pp. 7191–7199, 2025, doi: 10.1039/D5RA00204D.
  2. S. Colagiuri and A. Ceriello, “1. Detection of diabetes and intermediate hyperglycaemia, and prevention of type 2 diabetes,” Diabetes Res Clin Pract, vol. 222, p. 112145, Apr. 2025, doi: 10.1016/j.diabres.2025.112145.
  3. C.-H. Sia, O. Simon, P.-H. Loh, and K. K. Poh, “Atherosclerotic cardiovascular disease landscape in Singapore,” Front Cardiovasc Med, vol. 11, Apr. 2024, doi: 10.3389/fcvm.2024.1342698.
  4. K. E. Sleeman et al., “The escalating global burden of serious health-related suffering: projections to 2060 by world regions, age groups, and health conditions,” Lancet Glob Health, vol. 7, no. 7, pp. e883–e892, Jul. 2019, doi: 10.1016/S2214-109X(19)30172-X.
  5. L. Pereira and A. Valado, “Algae-Derived Natural Products in Diabetes and Its Complications—Current Advances and Future Prospects,” Life, vol. 13, no. 9, p. 1831, Aug. 2023, doi: 10.3390/life13091831.
  6. A. Bhatnagar and A. Mishra, “α-Glucosidase Inhibitors for Diabetes/Blood Sugar Regulation,” in Natural Products as Enzyme Inhibitors, Singapore: Springer Nature Singapore, 2022, pp. 269–283. doi: 10.1007/978-981-19-0932-0_12.
  7. R. P. Dash, R. J. Babu, and N. R. Srinivas, “Reappraisal and perspectives of clinical drug–drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus,” Xenobiotica, vol. 48, no. 1, pp. 89–108, Jan. 2018, doi: 10.1080/00498254.2016.1275063.
  8. Dr. R. Shrivastava, “Natural Products Revolutionizing and Innovative Drug Discovery and Development Strategies: Healthcare Challenges and Future Perspectives,” J Appl Bioanal, Jun. 2024, doi: 10.53555/jab.v10.002.
  9. C. A. Dehelean et al., “Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy,” Molecules, vol. 26, no. 4, p. 1109, Feb. 2021, doi: 10.3390/molecules26041109.
  10. S. Zafar, K. Sultan, S. Perveen, A. Parveen, N. Iqbal, and U. F. Gohar, “Henbane,” in Essentials of Medicinal and Aromatic Crops, Cham: Springer International Publishing, 2023, pp. 515–543. doi: 10.1007/978-3-031-35403-8_20.
  11. A. N. M. Alamgir, “Pharmacognostical Botany: Classification of Medicinal and Aromatic Plants (MAPs), Botanical Taxonomy, Morphology, and Anatomy of Drug Plants,” 2017, pp. 177–293. doi: 10.1007/978-3-319-63862-1_6.
  12. U. D. Renner, R. Oertel, and W. Kirch, “Pharmacokinetics and Pharmacodynamics in Clinical Use of Scopolamine,” Ther Drug Monit, vol. 27, no. 5, pp. 655–665, Oct. 2005, doi: 10.1097/01.ftd.0000168293.48226.57.
  13. S. Begum et al., “Study of anti-inflammatory, analgesic and antipyretic activities of seeds of Hyoscyamus niger and isolation of a new coumarinolignan,” Fitoterapia, vol. 81, no. 3, pp. 178–184, Apr. 2010, doi: 10.1016/j.fitote.2009.08.024.
  14. A. M. A. Hassane et al., “In Vitro and In Silico Antioxidant Efficiency of Bio-Potent Secondary Metabolites From Different Taxa of Black Seed-Producing Plants and Their Derived Mycoendophytes,” Front Bioeng Biotechnol, vol. 10, Jul. 2022, doi: 10.3389/fbioe.2022.930161.
  15. I. Bourais et al., “A Review on Medicinal Uses, Nutritional Value, and Antimicrobial, Antioxidant, Anti-Inflammatory, Antidiabetic, and Anticancer Potential Related to Bioactive Compounds of J. regia,” Food Reviews International, vol. 39, no. 9, pp. 6199–6249, Oct. 2023, doi: 10.1080/87559129.2022.2094401.
  16. S. Kadan, B. Saad, Y. Sasson, and H. Zaid, “In vitro evaluation of anti-diabetic activity and cytotoxicity of chemically analysed Ocimum basilicum extracts,” Food Chem, vol. 196, pp. 1066–1074, Apr. 2016, doi: 10.1016/j.foodchem.2015.10.044.
  17. Y.-M. Kim, M.-H. Wang, and H.-I. Rhee, “A novel α-glucosidase inhibitor from pine bark,” Carbohydr Res, vol. 339, no. 3, pp. 715–717, Feb. 2004, doi: 10.1016/j.carres.2003.11.005.
  18. S. Adisakwattana, T. Ruengsamran, P. Kampa, and W. Sompong, “In vitro inhibitory effects of plant-based foods and their combinations on intestinal α-glucosidase and pancreatic α-amylase,” BMC Complement Altern Med, vol. 12, no. 1, p. 110, Dec. 2012, doi: 10.1186/1472-6882-12-110.
  19. K. Mohanraj et al., “IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics,” Sci Rep, vol. 8, no. 1, p. 4329, Mar. 2018, doi: 10.1038/s41598-018-22631-z.
  20. J. Ru et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” J Cheminform, vol. 6, no. 1, p. 13, Dec. 2014, doi: 10.1186/1758-2946-6-13.
  21. R. Yadavalli, J. R. Peasari, P. Mamindla, Praveenkumar, S. Mounika, and J. Ganugapati, “Phytochemical screening and in silico studies of flavonoids from Chlorella pyrenoidosa,” Inform Med Unlocked, vol. 10, pp. 89–99, 2018, doi: 10.1016/j.imu.2017.12.009.
  22. Y. Rose et al., “RCSB Protein Data Bank: Architectural Advances Towards Integrated Searching and Efficient Access to Macromolecular Structure Data from the PDB Archive,” J Mol Biol, vol. 433, no. 11, p. 166704, May 2021, doi: 10.1016/j.jmb.2020.11.003.
  23. M. Saeed et al., “Assessment of Antidiabetic Activity of the Shikonin by Allosteric Inhibition of Protein-Tyrosine Phosphatase 1B (PTP1B) Using State of Art: An In Silico and In Vitro Tactics,” Molecules, vol. 26, no. 13, p. 3996, Jun. 2021, doi: 10.3390/molecules26133996.
  24. M. J. Iqbal, P. Loren, V. Burgos, and L. A. Salazar, “Multi-Target Anti-Aging Mechanisms of Multani Mitti (Fuller’s Earth): Integrating Enzyme Inhibition and Molecular Docking for Cosmeceuticals,” Cosmetics, vol. 12, no. 3, p. 124, Jun. 2025, doi: 10.3390/cosmetics12030124.
  25. A. Shahzad et al., “Integrated in vitro, in silico, and in vivo approaches to elucidate the antidiabetic mechanisms of Cicer arietinum and Hordeum vulgare extract and secondary metabolites,” Sci Rep, vol. 15, no. 1, p. 6620, Feb. 2025, doi: 10.1038/s41598-025-89642-5.
  26. G. Mustafa, S. Younas, H. S. Mahrosh, M. F. Albeshr, and E. A. Bhat, “Molecular Docking and Simulation-Binding Analysis of Plant Phytochemicals with the Hepatocellular Carcinoma Targets Epidermal Growth Factor Receptor and Caspase-9,” Molecules, vol. 28, no. 8, p. 3583, Apr. 2023, doi: 10.3390/molecules28083583.
  27. J. O. Unuofin and S. L. Lebelo, “Antioxidant Effects and Mechanisms of Medicinal Plants and Their Bioactive Compounds for the Prevention and Treatment of Type 2 Diabetes: An Updated Review,” Oxid Med Cell Longev, vol. 2020, pp. 1–36, Feb. 2020, doi: 10.1155/2020/1356893.
  28. C. O. Ajiboye et al., “Isolation, characterization, HPLC quantification, in-vitro and in-silico evaluations of coumarins and coumarolignans from Blighia unijugata stem with their chemotaxonomic significance,” Biochem Syst Ecol, vol. 120, p. 104950, Jun. 2025, doi: 10.1016/j.bse.2024.104950.
  29. A. S. Begum, S. S. Kumar, S. Gottapu, and K. Hira, “O-Glucoside of natural cleomiscosin-A: An attenuator of pro-inflammatory cytokine production,” Phytochem Lett, vol. 26, pp. 83–87, Aug. 2018, doi: 10.1016/j.phytol.2018.05.022.
  30. S. Sharma, S. K. Chattopadhyay, P. Trivedi, and D. U. Bawankule, “Synthesis and anti-inflammatory activity of derivatives of coumarino-lignoid, cleomiscosin A and its methyl ether,” Eur J Med Chem, vol. 45, no. 11, pp. 5150–5156, Nov. 2010, doi: 10.1016/j.ejmech.2010.08.027.
  31. F. Alam, Z. Shafique, S. T. Amjad, and M. H. H. Bin Asad, “Enzymes inhibitors from natural sources with antidiabetic activity: A review,” Phytotherapy Research, vol. 33, no. 1, pp. 41–54, Jan. 2019, doi: 10.1002/ptr.6211.

Copyright @2019 | Designed by: Open Journal Systems Chile Logo Open Journal Systems Chile Support OJS, training, DOI, Indexing, Hosting OJS

Code under GNU license: OJS PKP